Media Pack
News

Current Edition

JCS Volume 15 Issue 4
 
Regional News

Merck, Roche and J&J among pharma players weighing Russian operations amid humanitarian tightrope walk

You can’t buy a Coke, Frappuccino or Big Mac in Russia anymore, but cancer patients may still be able to get Merck’s megablockbuster Keytruda. While scores of Wester...
30 March 2022 Regional News cancer drugs | healthcare
Continue Reading →
Regional News

As Russian invasion persists, Roche, Teva, Novartis, Merck and more make renewed push to support besieged Ukraine

As Ukraine holds the line against the Russian invasion, pharma majors are making a renewed push to adjust operations in the region and supply the besieged country wit...
23 March 2022 Regional News Merck | Novartis
Continue Reading →
Regional News

Merck, putting $150M on the table, doubles down on pledge to tackle maternal mortality and health inequities

Around the world, a woman dies every two minutes from pregnancy or childbirth complications, most of them preventable. Merck has spent the last decade trying to chang...
11 January 2022 Regional News childbirth | complications
Continue Reading →
Regional News

Buffett’s Berkshire exited Merck investment just before COVID pill boost, further trimmed AbbVie and BMS holdings

Warren Buffett’s Berkshire Hathaway doesn’t appear to be the oracle of every market movement, at least not in the case of an investment in Merck & Co. The compan...
17 November 2021 Regional News COVID-19 pill | drug development
Continue Reading →
Regional News

With Merck’s oral COVID-19 med molnupiravir set for authorization, U.S. spends another $1B for 1.4 million courses

With molnupiravir, Merck & Co. and Ridgeback’s oral treatment for COVID-19, apparently on the doorstep of authorization, the U.S. has moved to secure additional d...
10 November 2021 Regional News COVID-19 | FDA
Continue Reading →
Regional News

Merck refiles $11.5B Acceleron deal with the FTC. But extending regulators’ review time only one benefit

Merck & Co.’s $11.5 billion bid for Acceleron Pharma is hitting a delay just as activist investors threaten to derail the deal altogether. Merck has withdrawn it...
2 November 2021 Regional News Acceleron Pharma | clinical research
Continue Reading →
Regional News

Novartis looks for silver lining in $2B canakinumab repurposing after 2nd lung cancer failure

Is autoinflammatory disease treatment Ilaris a potential new therapy for non-small cell lung cancer (NSCLC)? After two pivotal trial failures, the answer seems to be ...
26 October 2021 Regional News Ilaris | lung cancer
Continue Reading →
Regional News

Merck started its Acceleron pursuit at $160 per share, but CEO Davis balked at paying more than $180

Merck's new CEO Robert Davis has big shoes to fill after taking the reins from Kenneth Frazier at the start of July. Just two weeks into his tenure, though, his compa...
13 October 2021 Regional News Acceleron | buyout
Continue Reading →
Regional News

Merck and Ridgeback’s molnupiravir will be ‘complementary, but not a competitor’ to COVID-19 vaccines: analyst

What do Merck and Ridgeback’s eye-opening data, recently released for its antiviral molnupiravir on high-risk COVID-19 patients, mean for manufacturers of vaccines? ...
6 October 2021 Regional News antiviral molnupiravir | COVID-19
Continue Reading →
Regional News

Racing rival Pfizer, Merck’s Vaxneuvance makes its case for an FDA approval in children

Time is of the essence for Merck as the company races with rival Pfizer to gain an FDA approval for its next-generation pneumococcal vaccine in children. The longer ...
6 October 2021 Regional News children | FDA
Continue Reading →
 
 

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2024, All Rights Reserved – Powered by Teksyte